Lanifibranor significantly reduced APO-B with an AMD at EOT of −10 mg/dL (95%CI: −15 to −4, p < 0.001) with both doses (Table 1, Fig. 1D), as well as the APO-B/APO-A1 ratio with an AMD at EOT of −0.06 (95%CI: −0.11 to −0.01, p = 0.013) with 1200 mg and −0.08 (95%CI: −0.13 to −0.03, p = 0.002) with 800 mg (Table 1). This evidence concerns the gene APOA1 and age-related macular degeneration.